This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| P.1 lineage | |
|---|---|
| Name | P.1 lineage |
| Virus | SARS-CoV-2 |
| Lineage | P.1 |
| First detected | Manaus |
| First reported | Brazil |
| Notable mutations | K417T, E484K, N501Y |
| Classification | Variant of concern (VOC) |
P.1 lineage
P.1 lineage is a genetically distinct lineage of SARS-CoV-2 first identified in Manaus and associated with a major epidemic resurgence in Amazonas during late 2020. It attracted rapid international attention from WHO, PAHO, and national public health agencies including CDC and Public Health England because of changes in transmissibility, antigenicity, and potential impacts on vaccination and convalescent plasma efficacy. Researchers from institutions such as Fiocruz, University of Oxford, Imperial College London, Harvard University, and University of São Paulo contributed early genomic and epidemiological analyses.
P.1 lineage emerged amid co-circulation with other SARS-CoV-2 lineages and coincided with a steep rise in COVID-19 hospitalizations and deaths in Manaus despite evidence of prior high seroprevalence from studies by Fiocruz and researchers at Imperial College London. International scientific coordination involved groups at GISAID, Nextstrain, COG-UK Consortium, Wellcome Trust, and national sequencing programs in United States, United Kingdom, Japan, and Brazil to monitor spread. The lineage prompted travel advisories from governments such as United States Department of State and policy responses from ministries including Brazilian Ministry of Health.
Nomenclature assigned P.1 to the lineage by the global phylogenetic classification system developed by researchers at Andrew Rambaut’s group and the PANGO lineage framework used by GISAID and Nextstrain. Early genomic surveillance teams at Oswaldo Cruz Foundation, Instituto Leônidas e Maria Deane, and laboratories linked to University of São Paulo identified the cluster in samples from Manaus in December 2020. Phylogeographic analyses involving datasets from Brazil, United States, United Kingdom, Japan, and Canada traced probable origins to local transmission in Amazonas with subsequent exportation to international hubs such as São Paulo, Rio de Janeiro, Tokyo, New York City, and Paris.
P.1 lineage is defined by a constellation of spike protein changes including K417T, E484K, and N501Y, changes also of interest in lineages studied at Mount Sinai Hospital and La Jolla Institute for Immunology. Additional mutations occur in non-spike loci monitored by groups at NIH and ECDC. Structural biology teams at Scripps Research and Cold Spring Harbor Laboratory characterized effects on the ACE2 receptor interaction and neutralizing antibody binding, while neutralization assays were performed by researchers at Oxford Vaccine Group and Imperial College London to assess antigenic drift relative to strains isolated in Wuhan.
Epidemiological investigations combining datasets from Fiocruz, Instituto Evandro Chagas, Brazilian Ministry of Health, Johns Hopkins University, and European CDC suggested increased transmissibility compared with co-circulating lineages, inferred via reproductive number estimates and household secondary attack studies. International spread was documented in surveillance reports from Japan, CDC, Public Health Agency of Canada, and PHE, with introductions linked to travel from Brazil, regional connectivity across South America via air routes through São Paulo–Guarulhos International Airport and overland corridors into Argentina and Colombia. Modeling teams at Imperial College London and University of Cambridge evaluated scenarios for displacement of existing lineages and impacts on healthcare demand in cities including Manaus, São Paulo, and Rio de Janeiro.
Clinical case series collected by hospitals such as Hospital das Clínicas and analyses by academic centers including Harvard Medical School reported concerns about increased reinfection risk and reduction in neutralization by sera from convalescent patients and vaccine recipients. Laboratory studies from NIH, Imperial College, and University of Oxford measured decreases in neutralizing titers for some monoclonal antibodies and polyclonal sera, prompting reassessment of therapeutics such as monoclonal products developed by Regeneron and Eli Lilly. Vaccine effectiveness evaluations from Pfizer–BioNTech, AstraZeneca, and Sinovac Biotech programs were prioritized by regulators including European Medicines Agency and Brazilian Health Regulatory Agency.
Genomic surveillance networks including GISAID, COG-UK, Fiocruz network, and national public health laboratories expanded sequencing efforts to detect the lineage through whole-genome sequencing and targeted PCR assays developed by academic groups at CDC and University of Cambridge. International data sharing via GISAID and analytical platforms such as Nextstrain and PANGO enabled near-real-time tracking and lineage assignment, while diagnostic manufacturers including Thermo Fisher Scientific and Roche Diagnostics evaluated assay performance in the presence of signature mutations.
Public health responses involved accelerated vaccination campaigns by ministries in Brazil, travel restrictions enacted by governments such as Japan and United Kingdom, genomic surveillance scale-up funded by organizations including Wellcome Trust and Bill & Melinda Gates Foundation, and clinical guidance updates from WHO and national agencies. Non-pharmaceutical interventions implemented in affected municipalities included strengthening of hospital capacity at facilities like Hospital Universitário Getúlio Vargas, oxygen supply logistics coordinated with Brazilian Armed Forces, and communication campaigns led by Brazilian Ministry of Health in partnership with local authorities in Manaus and Amazonas. Ongoing international collaboration across WHO, PAHO, GISAID, and academic consortia continues to monitor evolutionary trajectories and inform policy.
Category:Variants of SARS-CoV-2